President & CEO of Cytokinetics Inc. (CYTK, Financial) Robert I Blum sells 1,000 shares of CYTK on 08/04/2009 at an average price of $3 a share.
CYTOKINETCS is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery development and commercialization of therapeutics. Similarly it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas including cancer and cardiovascular diseases. However the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. Cytokinetics Inc. has a market cap of $188.9 million; its shares were traded at around $3.11 with a P/E ratio of 11.5 and P/S ratio of 15.2.
Recent Trades of Cytokinetics Inc. by CEO:
Recent Trades of Cytokinetics Inc. by Directors and Officers:
CYTOKINETCS is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery development and commercialization of therapeutics. Similarly it is more and more uncommon for a biopharmaceutical company to tackle the pursuit of new treatments for multiple disease areas including cancer and cardiovascular diseases. However the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. Cytokinetics Inc. has a market cap of $188.9 million; its shares were traded at around $3.11 with a P/E ratio of 11.5 and P/S ratio of 15.2.
Recent Trades of Cytokinetics Inc. by CEO:
- Sell: President & CEO Robert I Blum sold 1,000 shares of CYTK stock on 07/22/2009 at the average price of $2.83; the price of the stock has increased by 9.89% since.
- Sell: President & CEO Robert I Blum sold 1,000 more shares of CYTK stock on 07/22/2009 at the average price of $2.83; the price of the stock has increased by 9.89% since.
- Sell: President & CEO Robert I Blum sold 1,000 more shares of CYTK stock on 07/22/2009 at the average price of $2.83; the price of the stock has increased by 9.89% since.
- Sell: President & CEO Robert I Blum sold 1,000 more shares of CYTK stock on 07/08/2009 at the average price of $2.72; the price of the stock has increased by 14.34% since.
- Sell: President & CEO Robert I Blum sold 1,000 more shares of CYTK stock on 06/22/2009 at the average price of $2.74; the price of the stock has increased by 13.5% since.
Recent Trades of Cytokinetics Inc. by Directors and Officers:
- Buy: Director Michael Schmertzler bought 1,522,840 shares of CYTK stock on 05/21/2009 at the average price of $1.97; the price of the stock has increased by 57.87% since.
- Sell: Executive Chairman James H Sabry sold 40,000 shares of CYTK stock on 06/29/2009 at the average price of $2.85; the price of the stock has increased by 9.12% since.
- Sell: Executive Chairman James H Sabry sold 60,000 more shares of CYTK stock on 06/05/2009 at the average price of $2.86; the price of the stock has increased by 8.74% since.
